Méndez BM

Language: Spanish
References: 10
Page: 31-34
PDF size: 128.25 Kb.

ABSTRACT

The treatment of patients with avian influenza in the countries affected by epidemic outbreaks had been focus in two principal ways, the support interventions, basic and advanced measures, and the use of antiviral agents. The interventions of basic support involve respiratory isolation and inhaled therapy measures. The advanced support, begins with the ingress from the patient to the intensive care unit, and involves the old monitoring systems, oxygen therapy, early tracheal intubation and mechanical ventilation. The main antiviral agents involve the adamantanatos (amantadina and rimantadina), and the inhibitors of neuraminidases (oseltamivir and zanamivir). The first it consider the election ones in open population at least the illness occurs with viruses with high suspicious of resistance to adamantanatos. If the patient is very ill and the way is available, the inhibitors of neuraminidases are the best choice. The actual recommendations have not a great level of evidence and are based in animal studies.

REFERENCES

1. Burkhead SK, Michaelson PG, Mair EA. Avian flu: What the otolaryngologist needs to know. Otolaryngology-Head and Neck Surgery 2006; 135: 663-670.

2. Boyd M, Clezy K, Lindley R, Pearce R. Pandemic influenza: clinical issues. MJA 2006; 185: S44-S47.

3. Heymann DL. SARS and emerging infectious diseases: A challenge to place global solidarity above national sovereignty. Ann Acad Med Singapore 2006; 35: 350-3.

4. Fleming DM, Zambon M. Update on influenza and other viral pneumonias. Infect Dis 2001; 14: 199-204.

5. Weir E, Wong T, Gemmill I. Avian influenza outbreak: Update www.cmaj.ca on Jan. 30, 2004. Revised Feb. 9, 2004.

6. Daughertya EL, Bransonb R, Rubinsonc L. Mass casualty respiratory failure. Curr Opin Crit Care 2007; 13: 51-56.

7. Tai DYH. SARS: How to manage future outbreaks? Ann Acad Med Singapore 2006; 35: 368-73.

8. Brooksa MJ, Joseph J, Sasadeuszb JJ, Tannocka GA. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what’s in the pipeline? Curr Opin Pulm Med 2004; 10: 197-203.

9. WHO Rapid Advice Guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. World Health Organization. 2006

10. Samson S, Wong Y, Path MRC, Kwok-yung Y. Avian influenza virus infections in humans. CHEST 2006; 129: 156-168.